Effect of Evening Primrose Oil on Korean Patients With Mild Atopic Dermatitis: A Randomized, Double-Blinded, Placebo-Controlled Clinical Study
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: Atopic dermatitis (AD) is related to a deficiency of delta-6-desaturase, an enzyme responsible for converting linoleic acid to gamma-linolenic acid (GLA). Evening primrose oil (EPO) as a source of GLA has been of interest in the management of AD. Objective: The aim of this randomized, double-blinded, placebo-controlled clinical study is to evaluate the efficacy and safety of EPO in Korean patients with AD. Methods: Fifty mild AD patients with an Eczema Area Severity Index (EASI) score of 10 or less were enrolled and randomly divided into two groups. The first group received an oval unmarked capsule containing 450 mg of EPO (40 mg of GLA) per capsule, while placebo capsules identical in appearance and containing 450 mg of soybean oil were given to the other group. Treatment continued for a period of four months. EASI scores, transepidermal water loss (TEWL), and skin hydration were evaluated in all the AD patients at the baseline, and in months 1, 2, 3, and 4 of the study. Results: At the end of month 4, the patients of the EPO group showed a significant improvement in the EASI score (p=0.040), whereas the patients of the placebo group did not. There was a significant difference in the EASI score between the EPO and placebo groups (p=0.010). Although not statistically significant, the TEWL and skin hydration also slightly improved in the EPO patients group. Conclusion: We suggest that EPO is a safe and effective medicine for Korean patients with mild AD.
Abstract
Background: Atopic dermatitis (AD) is related to a deficiency of delta-6-desaturase, an enzyme responsible for converting linoleic acid to gamma-linolenic acid (GLA). Evening primrose oil (EPO) as a source of GLA has been of interest in the management of AD. Objective: The aim of this randomized, double-blinded, placebo-controlled clinical study is to evaluate the efficacy and safety of EPO in Korean patients with AD. Methods: Fifty mild AD patients with an Eczema Area Severity Index (EASI) score of 10 or less were enrolled and randomly divided into two groups. The first group received an oval unmarked capsule containing 450 mg of EPO (40 mg of GLA) per capsule, while placebo capsules identical in appearance and containing 450 mg of soybean oil were given to the other group. Treatment continued for a period of four months. EASI scores, transepidermal water loss (TEWL), and skin hydration were evaluated in all the AD patients at the baseline, and in months 1, 2, 3, and 4 of the study. Results: At the end of month 4, the patients of the EPO group showed a significant improvement in the EASI score (p=0.040), whereas the patients of the placebo group did not. There was a significant difference in the EASI score between the EPO and placebo groups (p=0.010). Although not statistically significant, the TEWL and skin hydration also slightly improved in the EPO patients group. Conclusion: We suggest that EPO is a safe and effective medicine for Korean patients with mild AD.
참고문헌 (28)
- Thomas Bieber, "Atopic Dermatitis", Annals of Dermatology, 22(2), pp.125~137 (2010), 대한피부과학회
- Cork MJ, "Epidermal barrier dysfunction in atopic dermatitis", J Invest Dermatol, 129, pp.1892~1908 (2009)[DOI]
- McPherson T, "Current Understanding in Pathogenesis of Atopic Dermatitis", Indian J Dermatol, 61, pp.649~655 (2016)[DOI]
- Horrobin DF, "Essential fatty acid metabolism and its modification in atopic eczema", Am J Clin Nutr, 71(1 Suppl), pp.367S~372S (2000)[DOI]
- Wright S, "Essential fatty acids and the skin", Br J Dermatol, 125, pp.503~515 (1991)[DOI]
- Manku MS, "Reduced levels of prostaglandin precursors in the blood of atopic patients: defective delta-6-desaturase function as a biochemical basis for atopy", Prostaglandins Leukot Med, 9, pp.615~628 (1982)[DOI]
- Kerscher MJ, "Treatment of atopic eczema with evening primrose oil: rationale and clinical results", Clin Investig, 70, pp.167~171 (1992)
- Simon D, "Gamma-linolenic acid levels correlate with clinical efficacy of evening primrose oil in patients with atopic dermatitis", Adv Ther, 31, pp.180~188 (2014)[DOI]
- Senapati S, "Evening primrose oil is effective in atopic dermatitis: a randomized placebo-controlled trial", Indian J Dermatol Venereol Leprol, 74, pp.447~452 (2008)[DOI]
- Morse NL, "A meta-analysis of randomized, placebo-controlled clinical trials of Efamol evening primrose oil in atopic eczema. Where do we go from here in light of more recent discoveries?", Curr Pharm Biotechnol, 7, pp.503~524 (2006)[DOI]
- Bamford JT, "Oral evening primrose oil and borage oil for eczema", Cochrane Database Syst Rev, (4) (2013)
- 이지현, "아토피피부염학회 보고서: 한국 아토피피부염의 치료지침", 대한피부과학회지, 44(8), pp.907~913 (2006), 대한피부과학회
- Hanifin JM, "Diagnostic features of atopic dermatitis", Acta Derm Venerol (Stockh), 92, pp.44~47 (1980)
- Hanifin JM, "The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group", Exp Dermatol, 10, pp.11~18 (2001)[DOI]
- Eskin NAM, "Borage and evening primrose oil", Eur J Lipid Sci Tech, 110, pp.651~654 (2008)[DOI]
- Vieira BL, "Complementary and Alternative Medicine for Atopic Dermatitis: An Evidence-Based Review", Am J Clin Dermatol, 17, pp.557~581 (2016)[DOI]
- Muggli R, "Systemic evening primrose oil improves the biophysical skin parameters of healthy adults", Int J Cosmet Sci, 27, pp.243~249 (2005)[DOI]
- Wertz PW, "Essential fatty acids and epidermal integrity", Arch Dermatol, 123, pp.1381~1384 (1987)[DOI]
- McCusker MM, "Healing fats of the skin: the structural and immunologic roles of the omega-6 and omega-3 fatty acids", Clin Dermatol, 28, pp.440~451 (2010)[DOI]
- Belch JJ, "Evening primrose oil and borage oil in rheumatologic conditions", Am J Clin Nutr, 71(1 Suppl), pp.352S~356S (2000)[DOI]
- Manku MS, "Essential fatty acids in the plasma phospholipids of patients with atopic eczema", Br J Dermatol, 110, pp.643~648 (1984)[DOI]
- Bamford JT, "Atopic eczema unresponsive to evening primrose oil (linoleic and gammalinolenic acids)", J Am Acad Dermatol, 13, pp.959~965 (1985)[DOI]
- Berth-Jones J, "Placebo-controlled trial of essential fatty acid supplementation in atopic dermatitis", Lancet, 341, pp.1557~1560 (1993)[DOI]
- Bordoni A, "Evening primrose oil (Efamol) in the treatment of children with atopic eczema", Drugs Exp Clin Res, 14, pp.291~297 (1988)
- Schalin-Karrila M, "Evening primrose oil in the treatment of atopic eczema: effect on clinical status, plasma phospholipid fatty acids and circulating blood prostaglandins", Br J Dermatol, 117, pp.11~19 (1987)
- Humphreys F, "The effects of gamolenic acid on adult atopic eczema and premenstrual exacerbation of eczema", Eur J Dermatol, 4, pp.598~603 (1994)
- Yoon S, "The therapeutic effect of evening primrose oil in atopic dermatitis patients with dry scaly skin lesions is associated with the normalization of serum gamma-interferon levels", Skin Pharmacol Appl Skin Physiol, 15, pp.20~25 (2002)[DOI]
- 정보영, "Dose-Dependent Effects of Evening Primrose Oil in Children and Adolescents with Atopic Dermatitis", Annals of Dermatology, 25(3), pp.285~291 (2013), 대한피부과학회